Takeda Pharmaceutical Company Limited
TAKHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Sep 9, 2026
Scan Results
Daily timeframePart of the healthcare sector, Takeda Pharmaceutical Company Limited (TAK) is listed under Drug Manufacturers - Specialty & Generic. At a $58.50B market cap, Takeda Pharmaceutical Company Limited ranks as a large-cap company within healthcare. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience.
Market Cap
$58.50B
Beta
0.10
P/E (TTM)
—
P/E (Fwd)
34.57
EPS (TTM)
$-0.33
EPS (Fwd)
$0.53
ROE
-2.3%
ROA
2.7%
Cash
$460.98B
Total Debt
$5.54T
Free CF
$541.44B
52W Change
20.7%
Annual Financials
Cash vs Debt
Where TAK stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, TAK finished 6.96% above its 150-day moving average ($17.23) and 10.23% above its 200-day moving average ($16.72). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is TAK overbought or oversold?
At the September 3, 2026 close, TAK's RSI(14) was 69.3, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, TAK has $460.98B in cash with $5.54T in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Annual free cash flow of $541.44B supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of -2.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 2.7% is on the lower side, which is common in asset-heavy industries. Revenue has been uneven over recent years, ranging from $4.03T to $4.51T.
The relatively low beta of 0.10 suggests TAK is a less volatile holding compared to the broader index. Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. No single metric tells the full story. Reviewing TAK's risk profile alongside its fundamentals and technical indicators provides a more complete picture.